Get the Stockscreener App
8.05
5.48%
-0.35
After Hours:
7.78
-0.27
-3.35%
Transcode Therapeutics Inc stock is traded at $8.05, with a volume of 673.50K.
It is down -5.48% in the last 24 hours and up +111.17% over the past month.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
See More
Previous Close:
$8.40
Open:
$8.4
24h Volume:
673.50K
Relative Volume:
0.65
Market Cap:
$5.52M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0302
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
+44.37%
1M Performance:
+111.17%
6M Performance:
-10.89%
1Y Performance:
-67.70%
1-Day Range:
$7.44
$9.40
1-Week Range:
$6.20
$16.73
52-Week Range:
$2.66
$66.33
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.05 | 5.52M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
How Is The Market Feeling About TransCode Therapeutics? - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Stock market news: TransCode Therapeutics +133.97%, Diginex +27.49% among top gainers during mid day trading - Business Upturn
Are Investors Keen On Selling Holdings In GSK Plc ADR (NYSE: GSK)? - Stocks Register
Dow Inc (NYSE: DOW) Is A Buzzing Hot Stock - Stocks Register
Stock market today: Sentage Holdings +70.79%, Planet Image International +64.29% among top gainers in early trading - Business Upturn
TransCode Therapeutics Shares Are Surging Today: What's Going On? - Benzinga
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.93% - Investing.com UK
Clinical Trials News Live Feed - StockTitan
Transcode Therapeutics doses first patient in third cohort of Phase 1trial - TipRanks
TransCode's TTX-MC138 Cancer Trial Advances: First Patient Dosed in Cohort 3 with Doubled Dose - StockTitan
Transcode Therapeutics stock hits 52-week low at $3.20 - Investing.com India
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements - PR Newswire
TransCode Therapeutics Secures Nasdaq Listing Status After Meeting Critical Requirements - StockTitan
SABBY MANAGEMENT, LLC Acquires Shares in TransCode Therapeutics Inc - GuruFocus.com
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update - Defense World
Financial Analysis: TransCode Therapeutics (NASDAQ:RNAZ) & Eliem Therapeutics (NASDAQ:ELYM) - Defense World
HC Wainwright Has Optimistic Outlook of RNAZ FY2024 Earnings - Defense World
Analysts Issue Forecasts for RNAZ Q1 Earnings - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
H.C. Wainwright raises TransCode Therapeutics target following SRC go-ahead for Cohort 3 - Investing.com
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial - StreetInsider.com
TransCode advances to third patient group in cancer trial - Investing.com India
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Transcode announces SRC approved third cohort in TTX-MC138 clinical trial - TipRanks
RNAZTransCode Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Transcode Therapeutics stock hits 52-week low at $6.89 By Investing.com - Investing.com Canada
TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 - MSN
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
TransCode Therapeutics Raises $8M in Private Placement - TipRanks
Why TransCode Therapeutics (RNAZ) Stock Is Diving - Benzinga
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split - The Manila Times
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Meet Nasdaq Requirements | RNAZ Stock News - StockTitan
TransCode Therapeutics announces $8M private offering - MSN
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement - Yahoo Finance
TransCode secures $8 million in private placement - Investing.com India
TransCode secures $8 million in private placement By Investing.com - Investing.com Australia
TransCode Therapeutics, Inc. Announces $8 Million Private Placement - The Manila Times
TransCode Therapeutics Secures $8M Private Placement, Issues 21.2M Shares | RNAZ Stock News - StockTitan
TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding - Marketscreener.com
Transcode Therapeutics announces 1-for-33 reverse stock split - Yahoo Finance
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.46%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):